What is Acrux?
Acrux operates as a specialized pharmaceutical entity dedicated to the research, development, and commercialization of topical and transdermal prescription medicines. By focusing on innovative drug delivery mechanisms—including sprays, gels, creams, and specialized solutions—the company addresses critical gaps in patient convenience and treatment adherence. Its business model integrates in-house formulation and manufacturing expertise with strategic international partnerships, allowing the firm to bring regulated, high-quality skin-applied therapies to a diverse global patient base. This technical proficiency in drug delivery systems establishes Acrux as a key player in the evolving landscape of specialty medicine.
How much funding has Acrux raised?
Acrux has raised a total of $1.6M across 1 funding round:
Stock/Share Issuance
$1.6M
Stock/Share Issuance (2026): $1.6M, investors not publicly disclosed
Key Investors in Acrux
Undisclosed Investors
What's next for Acrux?
The recent influx of capital is expected to catalyze the next phase of the company's growth, likely focusing on the expansion of its pipeline and the strengthening of its manufacturing capabilities. As Acrux moves forward, the strategic deployment of these funds will be critical in scaling its reach within international markets and enhancing its portfolio of branded and generic drug delivery systems. By leveraging its core competencies in transdermal technology, the company is poised to address unmet clinical needs, potentially driving long-term value through improved therapeutic outcomes and expanded market penetration in the competitive pharmaceutical sector.
See full Acrux company page
